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We report the case of a 13-year-old girl with multiple recurrences of an aneurysmal bone cyst of the distal ﬁbula successfully treated
with denosumab and curettage. Aneurysmal bone cysts are locally aggressive lesions with high rates of recurrence. The novel use of
denosumab with curettage in a long bone showed a favorable outcome with no adverse events or signs of recurrence three years
after treatment.

1. Introduction
Aneurysmal bone cysts (ABCs) are rare, benign, locally
aggressive lesions that occur most frequently in the ﬁrst
or second decade of life [1]. The prevalence of ABCs is
0.14 cases per 100,000 individuals, and they constitute
approximately 1% of all bone tumors [1]. The most
common sites include the vertebral bodies and long bones,
particularly the metaphysis of the distal femur or proximal
tibia [2]. ABCs were initially thought to be caused by
vascular disturbances in the bone leading to increased
intraosseous pressure which caused local destruction and
distension [3]. More recent evidence shows a genetic
component, speciﬁcally, a translocation-induced upregulation of the ubiquitin-speciﬁc protease USP6 (Tre2) gene,
which favors a primary neoplastic process rather than a
mechanical or vascular one [4]. The majority are considered primary lesions; however, up to 30% can be considered secondary tumors arising from chondroblastomas,
osteoblastomas, nonossifying ﬁbromas, and other benign
osseous lesions [1].

Patients typically present after a nontraumatic episode with complaints of pain, swelling, or the presence
of a palpable mass [1]. Radiographic imaging shows an
expansile, eccentric, lytic lesion with thin cortices and
septae present. Cross-sectional MRI may reveal septations, contrast enhancement with edema, and “ﬂuidﬂuid levels” which correspond to a demarcation of blood
with diﬀerent densities [5].
Treatment generally consists of intralesional curetting
and bone grafting with or without adjuvant therapy. Wide
resection is considered for lesions that have destroyed the
bone, while for large tumors in the axial skeleton or pelvis,
embolization and sclerotherapy have been utilized. All of
these modalities have associated morbidity and risk of
complications. Curettage with or without bone grafting
has been shown to have a highly variable recurrence rate
of anywhere from 7 to 30% in larger studies [2, 6]. Younger age, open physes, increase in mitotic ﬁgures, and
increased cellularity have all been implicated in the high
rate of local recurrence [7, 8]. Denosumab, a monoclonal
antibody to the RANK ligand, has recently been used in
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a few cases and has been shown to decrease tumor burden
size, reduce pain, resolve associated neurologic symptoms,
and show evidence of radiographic healing [9–11]. In this
report, we discuss a speciﬁc case of an ABC with multiple
recurrences in a young patient treated with denosumab
followed by curettage and cementation who is recurrence
free three years later, without complications. The patient
and her mother provided consent for publication.

2. Case Report
A 13-year-old female initially presented with a history of
pain and swelling along her right distal ﬁbula. A physical
exam was remarkable for point tenderness along the distal
ﬁbula with no skin changes and an otherwise normal neurovascular examination. Radiographs obtained demonstrated a lytic, expansile, geographic lesion with no
cortical disruption or periosteal reaction (Figure 1). MRI
revealed a multiloculated, minimally enhancing, expansile
lesion (Figures 2 and 3).
She underwent an open biopsy which showed cyst-like
spaces ﬁlled with blood surrounded by ﬁbrous septa composed of a cellular proliferation of bland ﬁbroblasts, scattered multinucleated giant cells, and chronic inﬂammation
consistent with the diagnosis of an ABC (Figure 4). A curettage, application of phenol, and allograft bone grafting were
performed, and she was followed with serial radiographs. Six
months following surgery, she presented to the clinic complaining of pain with sprinting. Radiographs obtained
showed resorption of the bone graft indicating local recurrence. MRI showed a homogeneously lobulated, hyperintense lesion with multiple ﬂuid-ﬂuid levels conﬁrming the
recurrence (Figures 5 and 6). She underwent a repeat
extended curettage with the application of phenol and bone
grafting at about one year following her index procedure.
Approximately eleven months following her second
procedure and eighteen months following her index procedure, she again complained of pain in the right ankle with
exercise. Repeat radiographs demonstrated another recurrence. Since she had failed two operative treatments, a
referral to pediatric oncology was placed for the consideration of denosumab therapy for oﬀ-label use. The patient
and her mother elected to proceed with the initiation of
therapy after the risks including osteonecrosis of the jaw,
and hypocalcemia had been discussed. The regimen used
to treat giant cell tumor (GCT) was implemented which
consisted of subcutaneous denosumab (120 mg) given
every 4 weeks (with additional 120 mg SC doses on days
8 and 15 in cycle 1 only) for a total of 12 months [12].
She was administered vitamin D and calcium supplements
daily and 3 months after the last denosumab dose to mitigate her risk of hypocalcemia, and labs were checked
prior to each injection. Her pain improved following the
initiation of treatment, and she was asymptomatic at completion of therapy. Serial radiographs were obtained
throughout her treatment which showed increased mineralization and no further expansion of her lesion throughout the course of denosumab therapy (Figures 7 and 8).

Figure 1: AP and mortise radiographs of the ankle demonstrating a
lytic, expansile, geographic bone lesion with no cortical disruption.

One year following the initiation of denosumab therapy,
she underwent open biopsy, curettage with high-speed burring, and cement augmentation. The lesion was ﬁlled with
thickened calciﬁcations and septae. Her histopathology at
the time of surgery showed numerous fragmented bones
admixed with fragments of ﬁbrous connective tissue with
bland ﬁbroblasts with no signiﬁcant component of multinucleated giant cells present (Figure 9). She has been followed
for three years with clinical and radiographic examination,
has resumed all normal activity without pain, and has had
no recurrence of her disease (Figures 10 and 11).

3. Discussion
The term “aneurysmal bone cyst” was ﬁrst coined in 1942 by
Dr. Jaﬀe and Dr. Lichenstein when describing lesions in the
spine and pelvis [13]. The treatment at that time, curettage
and bone grafting to ﬁll the void, is still widely used today.
Modiﬁcations have been made since this initial description
including the use of a high-speed burr which showed a 12%
local recurrence rate in extremity [7]. Another study in the
spine showed no incidence of recurrence in eight patients
using the same surgical technique [14]. Although good outcomes following curettage and bone grafting have been
achieved, the recurrence rate following treatment is still
signiﬁcantly high as seen in our patient and noted in the
literature [2, 6]. This has led some authors to use adjuvant
therapy such as phenol in conjunction with curettage and
bone grafting. Phenol is thought to necrotize or “wash”
residual tumor cells following curettage and has shown a
recurrence rate of 7% compared to 41% when used with
curettage and bone grafting alone in simple bone lesions
[15]. Using phenol to treat ABCs, Bitzan et al. demonstrated no recurrences in 9 cases after surgery with
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Figure 2: STIR (short tau inversion recovery) weighted MRI of the
ankle showing 5 × 5.2 × 3.6 cm multiloculated, expansile lesion with
ﬂuid-ﬂuid levels.

Figure 3: T1 weighted MRI of the ankle showing 5 × 5.2 × 3.6 cm
multiloculated, slightly hyperintense compared to surrounding
muscle expansile lesion.

curettage, phenol, and bone grafting [16]. En bloc resection has the lowest risk of recurrence; however, the morbidity depending on the location is much higher.
Newer, pharmacologic treatments have recently been
evaluated in hopes to limit the morbidity associated with
surgery. The role of denosumab, a receptor activator of
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Figure 4: Photomicrographs demonstrating the wall of an ABC
partially lined by proliferation of bland ﬁbroblasts (Black arrow)
with underlying osteoclast-type giant cells (star) and blood
(hematoxylin and eosin, ×20).

Figure 5: T1 weighted MRI showing a homogeneously slightly
hyperintense to muscle lobulated lesion with multiple ﬂuidﬂuid levels.

nuclear kappa B ligand (RANKL) inhibitor, has been studied for the treatment of benign bone tumors including
giant cell tumor (GCT) as well as for metastatic bone disease. The RANK signaling pathway is essential for skeletal
homeostasis, and disruption of this pathway can cause
increased bone resorption. In a normal tissue, osteoblasts
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Figure 6: STIR (short tau inversion recovery) weighted MRI
showing a homogeneously lobulated, hyperintense lesion with
multiple ﬂuid-ﬂuid levels.

Figure 8: Posttreatment with denosumab after 1 year shows
increased mineralization and no further expansion or
cortical disruption.

Figure 7: Pretreatment with denosumab: mortise radiograph
showing a large lytic, expansile bone lesion with cortical disruption.

Figure 9: Photomicrographs taken after denosumab treatment
demonstrating ﬁbrous connective tissue with bland-looking
spindle cells (arrow), focal hemorrhage, and reactive bone
formation (star) admixed with scattered inﬂammatory cells;
multinucleated giant cells are absent.

secrete RANKL which binds to the RANK receptor on
osteoclasts causing increased bone resorption [17]. In GCT,
neoplastic stromal cells express high concentrations of
RANKL and activate RANK on osteoclast-like giant cells leading to increased bone destruction and osteolysis [18]. This
interaction of increased stimulation of RANKL/RANK has
also been linked to the pathophysiology seen in ABC in recent
studies [10, 19]. Denosumab is approved for the treatment of

osteoporosis, multiple myeloma, skeletal metastasis, and giant
cell tumor of bone (GCT) [20]. A recent clinical trial evaluating
the safety and eﬃcacy of denosumab treatment for GCT
showed promising results with fewer patients undergoing
surgery after treatment and those who did undergo surgery,
having a less morbid procedure than previously planned [21].
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Figure 10: Mortise radiographs taken at 10 months
following denosumab treatment and surgery demonstrating
no local recurrence.
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lesion. More recently, two cases of ABC in long bones, one
of which was recurrent, have been treated with denosumab
for an average of 7 months followed by curettage and bone
grafting with histologic compete response to treatment
with a median of 23-month follow-up [22]. Kurucu et al.
[23] treated nine cases of ABC with denosumab for an
average of 12 months, of which two eventually needed
surgery. Clinical symptoms including pain and limping
regressed completely in 3 months, and eight out of nine
lesions decreased in size and number of cysts. At the time
of treatment for our patient, we mirrored the typical length
of time for denosumab treatment for GCT, which was
close to a year. However, current trends are for treatment
lasting 3-4 months prior to surgical intervention for GCT.
We chose to present this case given the over 3-year followup which is longer than previously reported in [12, 22, 23].
Although segments of the ﬁbula are resectable, resection of
the distal ﬁbula can lead to lifelong ankle instability, even
with reconstruction, so we chose to preserve it.
The emerging safety data in the pediatric population
should be considered when selecting denosumab and providing informed consent to patients and families. Diﬀerent
from adults and seemingly rather common in patients
under 10 years of age, rebound hypercalcemia has been
reported 3-4 months following the last dose of denosumab
[23, 24]. While an upper age limit has not been determined, this may correlate with skeletal maturity and there
are few published reports in teens [20, 23]. Our patient
was 14 at the start of her denosumab treatment, close to
the average age of female skeletal maturity. Furthermore,
her radiographs showed closing growth plates. We did
not observe symptoms consistent with hypercalcemia in
this patient who was close to skeletal maturity.

4. Conclusion

Figure 11: Mortise radiographs taken at 3 years following
denosumab treatment and surgery demonstrating no local
recurrence.

There have been several case reports highlighting the
eﬃcacy of denosumab in the spine and sacrum, but very
few have reported on outcomes in long bones. Using
denosumab for a recurrent ABC of the distal radius, Pauli
et al. [22] were able to consolidate a locally aggressive and
destructive lesion into a resectable lesion and implement
limb-preserving surgery in an otherwise unresectable

Our ﬁndings support the use of denosumab for those
lesions that are locally aggressive or unresectable due to
location or in patients with failed primary treatment and
multiple recurrences. The utilization of cement, in addition
to providing immediate structural support in this now
skeletally mature patient, may have also added additional
adjuvant treatment to the lesion with its exothermic reaction during curing. We were able to preserve limb and
function, and our patient tolerated denosumab very well.
Considerations for this therapy include the risk of osteonecrosis of the jaw, the need for daily calcium supplementation, and it being contraindicated in pregnancy. It
remains unclear if denosumab would decrease the risk of
recurrence in a population of patients with ABC. Further
studies evaluating long-term results with more cases are
needed to better estimate eﬃcacy of the use of denosumab
for complicated ABCs not amenable to resection or in
cases responding to surgery alone.
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